Cystic Echinococcosis (CE) is a parasitic infection caused by the larval stage of Echinococcus granulosus. Exploring safe and effective scolicidal agents for the surgery is an urgent need for the successful treatment of CE. This study aimed to determine scolicidal activity of the synthesized chitosan nanoparticles. Physicochemical properties of synthesized nanoparticles were determined by using DLS, FTIR, and SEM. Different concentrations of chitosan nanoparticles from 125 to 1000 μg/ml were examined at different incubation times (10, 60, 120, and 180 min). Scolicidal and cytotoxic activity of chitosan nanoparticles were confirmed by eosin exclusion and hemolysis activity tests. FTIR spectra, zeta potential (+42 ± 2.08) and PDI (0.388 ± 0.034) value revealed that the chitosan nanoparticles were synthesized. Significant differences among the scolicidal effects of chitosan nanoparticles were observed in comparison to the control treatments and highest scolicidal activity was observed at 1000 μg/ml after 180 min exposure time. Hemolytic activity was not significant at all concentrations of chitosan nanoparticles. Our findings support the hypothesis that Chitosan nanoparticles have the potential to be a safe and efficient scolicidal agent candidate at very low concentrations and in a wide range of exposure time. Further in vivo studies are recommended to evaluate chitosan nanoparticle efficacy before clinical application.
DeplazesPRinaldiLRojasCA, et al. Global distribution of alveolar and cystic echinococcosis. Adv Parasitol2017; 95: 315–493.
2.
EckertJDeplazesP.Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern. Clin Microbiol Rev2004; 17: 107–135.
3.
ShafieiRTeshniziSHKalantarK, et al. The seroprevalence of human cystic echinococcosis in Iran: a systematic review and meta-analysis study. J Parasitol Res2016; 2016: 1425147.
4.
da SilvaAM. Human echinococcosis: a neglected disease. Gastroenterol Res Pract2010; 2010: 583297.
5.
WuXPengXZhangS, et al. Formation mechanisms of the fibrous capsule around hepatic and splenic hydatid cyst. Chin J Parasitol Parasit Dis2004; 22: 1–4.
6.
KernP.Echinococcus granulosus infection: clinical presentation, medical treatment and outcome. Langenbeck’s Arch Surg2003; 388: 413–420.
7.
RinaldiFBrunettiENeumayrA, et al. Cystic echinococcosis of the liver: a primer for hepatologists. World J Hepatol2014; 6: 293.
8.
LiuCSZhangHBLeiW, et al. An alternative mebendazole formulation for cystic echinococcosis: the treatment efficacy, pharmacokinetics and safety in mice. Parasit Vectors2014; 7: 589.
9.
EkciB.Scolicidal agent use in hydatid cysts and complications. Yeditepe Med J2011; 5: 379–384.
10.
KilicogluBKismetKKilicogluSS, et al. Effects of honey as a scolicidal agent on the hepatobiliary system. World J Gastroenterol2008; 14: 2085.
11.
PuryanKKaradayiKTopcuO, et al. Chlorhexidine gluconate: an ideal scolicidal agent in the treatment of intraperitoneal hydatidosis?World J Surg2005; 29: 227–230.
12.
MorrisDLRichardsKS.Hydatid disease: current medical and surgical management. London: Butterworth-Heinemann, 1992.
13.
LashkarizadehMRAsgaripourKDezakiES, et al. Comparison of scolicidal effects of amphotricin B, silver nanoparticles, and Foeniculum vulgare mill on hydatid cysts protoscoleces. Iran J Parasitol2015; 10: 206.
14.
KashefNHuangYYHamblinMR.Advances in antimicrobial photodynamic inactivation at the nanoscale. Nanophotonics2017; 6(5): 853–879.
15.
CosPVlietinckAJBergheDV, et al. Anti-infective potential of natural products: how to develop a stronger in vitro ‘proof-of-concept’. J Ethnopharmacol2006; 106: 290–302.
16.
YonesDATaherGAIbraheimZZ.In vitro effects of some herbs used in Egyptian traditional medicine on viability of protoscolices of hydatid cysts. Korean J Parasitol2011; 49: 255.
17.
GhormadeVDeshpandeMVPaknikarKM.Perspectives for nano-biotechnology enabled protection and nutrition of plants. Biotechnol Adv2011; 29: 792–803.
18.
BharaliDJSiddiquiIAAdhamiVM, et al. Nanoparticle delivery of natural products in the prevention and treatment of cancers: current status and future prospects. Cancers2011; 3: 4024–4045.
19.
ShojaeeSFirouzehNKeshavarzH, et al. Nanosilver colloid inhibits Toxoplasma gondii tachyzoites and bradyzoites in vitro. Iran J Parasitol2019; 14: 362.
20.
SaravananSVimalrajSAnuradhaD.Chitosan based thermoresponsive hydrogel containing graphene oxide for bone tissue repair. Biomed Pharmacother2018; 107: 908–917.
21.
KeanTThanouM.Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev2010; 62: 3–11.
22.
AliSWRajendranSJoshiM.Synthesis and characterization of chitosan and silver loaded chitosan nanoparticles for bioactive polyester. Carbohydr Polym2011; 83: 438–446.
23.
CheblMMoussaZPeurlaM, et al. Polyelectrolyte mediated nano hybrid particle as a nano-sensor with outstandingly amplified specificity and sensitivity for enzyme free estimation of cholesterol. Talanta2017; 169: 104–114.
24.
PerinelliDRFagioliLCampanaR, et al. Chitosan-based nanosystems and their exploited antimicrobial activity. Eur J Pharm Sci2018; 117: 8–20.
25.
CheblMAbiadMGMoussaZ, et al. Two modes of associations of curcumin with pre-and nanoaggregated chitosan oligosaccharide lactate: ionic strength and hydrophobic bile salt modulate partition of drug and self-assembly process. J Phys Chem C2016; 120: 11210–11224.
26.
TayelAAMoussaSOpwisK, et al. Inhibition of microbial pathogens by fungal chitosan. Int J Biol Macromol2010; 47: 10–14.
27.
XuJZhaoXHanX, et al. Antifungal activity of oligochitosan against Phytophthora capsici and other plant pathogenic fungi in vitro. Pestic Biochem Physiol2007; 87: 220–228.
28.
GaafarMMadyRDiabR, et al. Chitosan and silver nanoparticles: promising anti-toxoplasma agents. Exp Parasitol2014; 143: 30–38.
29.
EslaminejadTNematollahi-MahaniSNAnsariM.Cationic β-cyclodextrin–chitosan conjugates as potential carrier for pmCherry-C1 gene delivery. Mol Biotechnol2016; 58: 287–298.
30.
SmythJBarrettN.Procedures for testing the viability of human hydatid cysts following surgical removal, especially after chemotherapy. Trans R Soc Trop Med Hyg1980; 74: 649–652.
31.
HenkelmanSRakhorstGBlantonJ, et al. Standardization of incubation conditions for hemolysis testing of biomaterials. Mater Sci Eng C2009; 29: 1650–1654.
32.
MishraAChaudharyN.Study of povidone iodine loaded hydrogels as wound dressing material. Trends Biomater Artif Organs2010; 23: 122–128.
33.
MahmoudvandHKheirandishFDezakiES, et al. Chemical composition, efficacy and safety of Pistacia vera (var. Fandoghi) to inactivate protoscoleces during hydatid cyst surgery. Biomed Pharmacother2016; 82: 393–398.
34.
RejinoldNSMuthunarayananMMuthuchelianK, et al. Saponin-loaded chitosan nanoparticles and their cytotoxicity to cancer cell lines in vitro. Carbohydr Polym2011; 84: 407–416.
35.
SaharanVMehrotraAKhatikR, et al. Synthesis of chitosan based nanoparticles and their in vitro evaluation against phytopathogenic fungi. Int J Biol Macromol2013; 62: 677–683.
36.
HarandiMFBudkeCMRostamiS.The monetary burden of cystic echinococcosis in Iran. PLoS Negl Trop Dis2012; 6: e1915.
37.
ButtenschoenKButtenschoenDC.Echinococcus granulosus infection: the challenge of surgical treatment. Langenbeck’s Archiv Surg2003; 388: 218–230.
38.
MinceaMNegrulescuAOstafeV.Preparation, modification, and applications of chitin nanowhiskers: a review. Rev Adv Mater Sci2012; 30: 225–242.
39.
PhaechamudT.Hydrophobically modified chitosans and their pharmaceutical applications. J Pharm Sci Technol2008; 1: 2–9.
40.
Rahimi-EsboeiBFakharMChabraA, et al. In vitro treatments of Echinococcus granulosus with fungal chitosan, as a novel biomolecule. Asian Pac J Trop Biomed2013; 3: 811.
41.
GhadiAMahjoubSTabandehF, et al. Synthesis and optimization of chitosan nanoparticles: potential applications in nanomedicine and biomedical engineering. Caspian J Intern Med2014; 5: 156.
42.
KhanIKhanMUmarMN, et al. Nanobiotechnology and its applications in drug delivery system: a review. IET Nanobiotechnol2015; 9: 396–400.
43.
ShnawaBH.Advances in the use of nanoparticles as anti-cystic echinococcosis agents: a review article. J Pharm Res Int2018; 24: 1–14.
44.
NapooniSDelavariMArbabiM, et al. Scolicidal effects of chitosan–curcumin nanoparticles on the hydatid cyst protoscolices. Acta Parasitol2019; 64(2): 367–375.
45.
FakharMChabraARahimi-EsboeiB, et al. In vitro protoscolicidal effects of fungal chitosan isolated from Penicillium waksmanii andPenicillium citrinum. J Parasit Dis2015; 39: 162–167.
46.
AliMAfzalMVermaM, et al. Improved antifilarial activity of ivermectin in chitosan–alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi. Parasitol Res2013; 112: 2933–2943.
47.
Danesh-BahreiniMAShokriJSamieiA, et al. Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. Int J Nanomed2011; 6: 835.
48.
JiangSHuaELiangM, et al. A novel immunosensor for detecting toxoplasma gondii-specific IgM based on goldmag nanoparticles and graphene sheets. Colloids Surf B: Biointerfaces2013; 101: 481–486.
49.
TeimouriAAzamiSJKeshavarzH, et al. Anti-toxoplasma activity of various molecular weights and concentrations of chitosan nanoparticles on tachyzoites of RH strain. Int J Nanomed2018; 13: 1341.
50.
SharafiSMSefiddashtiRRSaneiB, et al. Scolicidal agents for protoscolices of Echinococcus granulosus hydatid cyst: review of literature. J Res Med Sci2017; 22: 92.
51.
ZohraMFawziaA.Hemolytic activity of different herbal extracts used in Algeria. Int J Pharm Sci Res2014; 5: 8495–8494.
52.
SinghalJPRayAR.Synthesis of blood compatible polyamide block copolymers. Biomaterials2002; 23: 1139–1145.
53.
ChenYMohanrajVJWangF, et al. Designing chitosan-dextran sulfate nanoparticles using charge ratios. AAPS PharmSciTech2007; 8: 131–139.
54.
FarahSDoloffJCAndersonG, et al. Crosslinked chitosan nanoparticles and chemical modifications for drug delivery applications. Polymeric drug delivery techniques: Translating polymer science for drug delivery, Sigma-Aldrich2015; 1: 18–21.
55.
GanQWangTCochraneC, et al. Modulation of surface charge, particle size and morphological properties of chitosan–TPP nanoparticles intended for gene delivery. Colloids Surf B: Biointerfaces2005; 44: 65–73.
56.
ChungYCSuYPChenCC, et al. Relationship between antibacterial activity of chitosan and surface characteristics of cell wall. Acta Pharmacol Sin2004; 25: 932–936.
57.
CostaJSilvaNSarmentoB, et al. Potential chitosan-coated alginate nanoparticles for ocular delivery of daptomycin. Eur J Clin Microbiol Infect Dis2015; 34: 1255–1262.
58.
YienLZinNMSarwarA, et al. Antifungal activity of chitosan nanoparticles and correlation with their physical properties. Int J Biomater2012; 2012: 632698.
59.
PattaniAPatravaleVBPanickerL, et al. Immunological effects and membrane interactions of chitosan nanoparticles. Mol Pharm2009; 6: 345–352.
60.
FouadDRG. Chitosan as an antimicrobial compound: modes of action and resistance mechanisms. Mathematisch-Naturwissenschaftliche Fakultät, Universität Bonn, 2008.
61.
BarabadiHHonaryS.Biofabrication of gold and silver nanoparticles for pharmaceutical applications. Pharm Biomed Res2016; 2(1):1–7.
62.
GoyRCBrittoDdAssisOB.A review of the antimicrobial activity of chitosan. Polímeros2009; 19: 241–247.
63.
ShinYYooDIMinK.Antimicrobial finishing of polypropylene nonwoven fabric by treatment with chitosan oligomer. J Appl Polym Sci1999; 74: 2911–2916.
64.
AndresYGiraudLGerenteC, et al. Antibacterial effects of chitosan powder: mechanisms of action. Environ Technol2007; 28: 1357–1363.
65.
HongpattarakereTRiyaphanO.Effect of deacetylation conditions on antimicrobial activity of chitosans prepared from carapace of black tiger shrimp (Penaeus monodon). Sonklanakarin J Sci Technol2008; 30: 1.
